XTLB · XTL Biopharmaceuticals
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $2.02
Note written ·
Price against the kill line
20.8% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $2.02, on record since 11 November 2026. The shares are down 38.5% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $2.02, the highest close of the last 20 sessions, which would show the shares leading again. A disclosed start of a Psyga human trial or a binding ibogaine partner would also show the case turning.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Filed figures are not available: no quarterly report in US GAAP with the SEC (a foreign filer reports on Form 20-F or 40-F).
All filed numbers
What XTL Biopharmaceuticals reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): the share of shares outstanding is not available, 1.0 days of average trading to cover, −30.9% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $0 | $0 |
The thesis
XTL Biopharmaceuticals' pivot into psychedelic medicine through its Psyga subsidiary has no reported trial start or binding partner, and the shares are more likely to lag the S&P 500 over the next three months. A disclosed human-trial start or a binding ibogaine partner would reopen the case; the 20 November 2026 external-director deadline and the escrow release around 30 December 2026 are the nearer tests.
The shares closed at $1.64 on 12 November 2026, down 41.1% over three months. They sit below the $2.70 per-share price of the 30 June 2026 private placement, so the market is not paying for the pivot at the level where new money came in. The newest Form 6-K on the SEC's EDGAR filing list is dated 14 October 2026, the board-change report.
Bullish and bearish views on XTL Biopharmaceuticals Ltd.
The bull case on XTL Biopharmaceuticals Ltd. (XTLB), in brief: the pivot has operating assets. The bear case: the shares trade below the financing price.
Bull case
- The pivot has operating assets. The 29 April 2026 filing described Psyga's licensed, GMP-ready (good manufacturing practice) facility for psychedelic active ingredients and seven approved Phase 2a trials. These are company descriptions of approvals and capacity, not reported trial starts or sales.
- The acquisition closed. XTL acquired approximately 83.40% of Psyga's fully diluted capital on 30 June 2026, so trial execution sits inside a controlled subsidiary. 30 June 2026 Form 6-K
- Progress has a dated test. The 2025 annual report filed 30 June 2026 ties the first acquisition milestone to the start of at least three clinical trials within twelve months of closing.
- Listing status was restored. Nasdaq confirmed restored compliance on 20 July 2026, which removed an immediate delisting question. July 2026 Form 6-K
Bear case
- The shares trade below the financing price. The 30 June 2026 placement raised $1.5 million at $2.70 per American Depositary Share (ADS), with Series A and B warrants attached. The close of $1.64 on 12 November 2026 is below that price.
- Further dilution is built into the terms. The placement allows Series C warrants after a lower-priced financing. The acquisition terms add shares or warrants for 8.34% of capital per milestone, up to 25% in total. ADSs issued to Psyga holders sit in escrow until the earlier of six months after closing or the first milestone.
- The company carries a going-concern warning. The 2025 Form 20-F filed 30 June 2026 contains it, and the $1.5 million raised does not remove it.
- Nasdaq oversight persists. The 20 July 2026 letter imposed a one-year Mandatory Panel Monitor, so a new equity-rule deficiency in that period has no ordinary cure period.
- An external director is leaving. Iris Shapira Yalon told the company on 12 October 2026 that she is resigning for personal reasons, effective at the earlier of her successor's election or 20 November 2026. The board approved Gilai Dolev as replacement on 14 October 2026, subject to a shareholder vote.
Price setup
The shares closed at $1.64 on 12 November 2026. The 52-week closing low is $1.53, set on 9 November 2026, and the 52-week high is $16.48 (intraday, 12 November 2025), so the last close is 90.0% below it. The 3-month change is −41.1% against a close of $2.79 on 14 August 2026.
The 50-day average of adjusted closes is $2.07 and the 200-day average is $2.61, both above the last close. Closes between 5 November 2026 and 12 November 2026 ranged from $1.53 to $1.71, so the shares have stayed in a narrow band just above the closing low rather than rebounding.
No company news has followed the 14 October 2026 filing, and XTL has no scheduled quarterly earnings date as a foreign private issuer. The one dated supply item is the escrow on ADSs issued to Psyga holders, which can release around 30 December 2026.
Catalysts ahead
- 20 November 2026: Latest effective date of external director Iris Shapira Yalon's resignation. If shareholders have not elected Gilai Dolev by then, the board has a vacancy while the company is under Nasdaq monitoring.
- ~30 December 2026 (est.): Six-month escrow on American Depositary Shares issued to Psyga holders ends. Releasable shares add to potential supply unless a milestone is met first.
- ~30 June 2027 (est.): Deadline to initiate at least three Psyga clinical trials. The first explicit operating test of the Psyga pivot.
What would change the view
A daily close above $2.02, the highest close of the last 20 sessions, which would show the shares leading again. A disclosed start of a Psyga human trial or a binding ibogaine partner would also show the case turning.
What it trades with
The shares trade on company-specific financing, listing and governance news rather than a sector move. Psychedelic-therapy developers are the nearest peer group, but XTL's microcap size, going-concern warning and Nasdaq monitoring set it apart from them.
The evidence, claim by claim (6)
- XTL acquired approximately 83.40% of Psyga's fully diluted capital on 30 June 2026. 30 June 2026 Form 6-K · as of
- The 30 June 2026 private placement raised $1.5 million at $2.70 per American Depositary Share and included Series A and Series B warrants. 30 June 2026 Form 6-K · as of
- Nasdaq confirmed restored compliance and imposed a one-year Mandatory Panel Monitor. 21 July 2026 Form 6-K · as of
- External director Iris Shapira Yalon resigns effective at the earlier of her successor's election or 20 November 2026; the board approved Gilai Dolev as replacement on 14 October 2026, subject to a shareholder vote. 14 October 2026 Form 6-K · as of
- The newest Form 6-K on the SEC EDGAR list for XTL (CIK 1023549) is dated 14 October 2026. SEC EDGAR filing list · as of
- The shares closed at $1.64 on 12 November 2026, down 41.1% over three months, after a 52-week closing low of $1.53 on 9 November 2026. Adjusted daily closes · as of
Sources